Published in Lab Business Week, February 5th, 2006
In accordance with the trial's design, eligible patients were randomized to receive either eculizumab or placebo in a 6-month treatment phase. Eculizumab is a monoclonal antibody drug that selectively blocks terminal complement, a part of the immune system that is implicated in PNH red blood cell destruction. There currently is no drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week